Binimetinib is an oral selective MEK 1/2 inhibitor currently FDA approved in the US for use in combination with BRAF inhibitor encorafenib in adult patients with unresectable BRAFV600 altered melanoma and non-small cell lung cancer. The gene discussed is BRAF; the disease is melanoma.